Alkermes plc $ALKS Stock: Fisher Asset Management LLC Grows Stake

Fisher Asset Management LLC grew its holdings in Alkermes plc (NASDAQ:ALKS – Free Report) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 433,263 shares of the company’s stock after acquiring an additional 14,161 shares during the period. Fisher Asset Management LLC’s holdings in Alkermes were worth $17,556,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ALKS. Maryland State Retirement & Pension System increased its stake in shares of Alkermes by 54.1% in the 3rd quarter. Maryland State Retirement & Pension System now owns 37,347 shares of the company’s stock worth $1,513,000 after purchasing an additional 13,105 shares in the last quarter. Illinois Municipal Retirement Fund raised its holdings in Alkermes by 36.2% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 114,142 shares of the company’s stock worth $4,625,000 after purchasing an additional 30,368 shares during the period. M&G PLC bought a new position in Alkermes in the 3rd quarter worth $14,368,000. Allspring Global Investments Holdings LLC raised its holdings in Alkermes by 236.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 85,682 shares of the company’s stock worth $3,474,000 after purchasing an additional 60,188 shares during the period. Finally, Pictet Asset Management Holding SA lifted its position in Alkermes by 20.4% during the third quarter. Pictet Asset Management Holding SA now owns 1,009,318 shares of the company’s stock valued at $41,012,000 after purchasing an additional 171,292 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Craig Hopkinson sold 9,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $46.99, for a total value of $422,910.00. Following the completion of the transaction, the executive vice president owned 65,389 shares of the company’s stock, valued at approximately $3,072,629.11. This represents a 12.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Gaffin sold 2,035 shares of the stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $46.17, for a total value of $93,955.95. Following the completion of the sale, the executive vice president owned 219,353 shares of the company’s stock, valued at $10,127,528.01. The trade was a 0.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 15,103 shares of company stock worth $697,973. 4.59% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ALKS shares. Robert W. Baird set a $61.00 target price on Alkermes in a research report on Wednesday, November 4th. HC Wainwright upped their price target on Alkermes from $43.00 to $50.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 4th. Needham & Company LLC restated a “buy” rating and issued a $62.00 price target on shares of Alkermes in a research report on Monday, September 21st. Mizuho raised Alkermes to a “strong-buy” rating in a research note on Wednesday, September 16th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Alkermes in a research report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $55.73.

Check Out Our Latest Analysis on Alkermes

Alkermes Price Performance

Shares of NASDAQ:ALKS opened at $47.03 on Monday. The company has a market capitalization of $7.90 billion, a P/E ratio of -2,350.32 and a beta of 0.32. Alkermes plc has a 1-year low of $27.00 and a 1-year high of $55.67. The firm’s 50 day simple moving average is $43.67 and its two-hundred day simple moving average is $41.13. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.42 and a quick ratio of 2.02.

Alkermes (NASDAQ:ALKS – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.17. The firm had revenue of $480.13 million during the quarter, compared to analysts’ expectations of $463.48 million. Alkermes had a negative net margin of 0.02% and a positive return on equity of 0.40%. The company’s revenue for the quarter was up 21.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.49 earnings per share. Research analysts expect that Alkermes plc will post -0.52 EPS for the current fiscal year.

Alkermes Profile

(Free Report)

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.

Read More

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.